Oxogestone
Clinical data
Other namesOxagestone; Oxagesterone; Oxogesterone; 20β-Hydroxy-19-norprogesterone; (20R)-20-Hydroxy-19-norpregn-4-en-3-one
Identifiers
  • (8R,9S,10R,13S,14S,17S)-17-[(1R)-1-hydroxyethyl]-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H30O2
Molar mass302.458 g·mol−1
3D model (JSmol)
  • CC(C1CCC2C1(CCC3C2CCC4=CC(=O)CCC34)C)O
  • InChI=1S/C20H30O2/c1-12(21)18-7-8-19-17-5-3-13-11-14(22)4-6-15(13)16(17)9-10-20(18,19)2/h11-12,15-19,21H,3-10H2,1-2H3/t12-,15+,16-,17-,18-,19+,20-/m1/s1
  • Key:CNOGNHFPIBORED-JIKCGYBYSA-N

Oxogestone (INNTooltip International Nonproprietary Name), also known as 20β-hydroxy-19-norprogesterone, is a progestin of the 19-norprogesterone group which was synthesized in 1953 and was developed as an injectable hormonal contraceptive in the early 1970s but was never marketed.[1][2][3][4][5] A C20β phenylpropionate derivative, oxogestone phenpropionate, also exists.[1]

References

  1. ^ a b Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 919–. ISBN 978-1-4757-2085-3.
  2. ^ Milne GW (8 May 2018). Drugs: Synonyms and Properties: Synonyms and Properties. Taylor & Francis. pp. 1577–. ISBN 978-1-351-78989-9.
  3. ^ Farkas M, Szontágh FE (March 1972). "Clinical experiences concerning the intramuscular contraceptive oxogestone". Acta Europaea Fertilitatis. 3 (1): 37–43. PMID 4679651.
  4. ^ Ruíz Velasco V, Alisedo Aparicio LE (1972). "[Side effects of depot contraceptives]". La Prensa Medica Mexicana (in Spanish). 37 (1): 25–29. PMID 5032612.
  5. ^ Bassol S, Garza-Flores J (May 1994). "Review of ovulation return upon discontinuation of once-a-month injectable contraceptives". Contraception. 49 (5): 441–453. doi:10.1016/0010-7824(94)90003-5. PMID 8045131.
Categories